Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | HCK | P08631 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875117 | 0.90 | KDM4E (0.34) | HTR6KDM4EALDH1A1TP53HPGD | |
| SCHEMBL10117911 | 0.90 | PIK3CD (0.43) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL29820909 | 0.79 | HTR6 (0.46) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL10193516 | 0.79 | BUB1 (0.40) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL1373109 | 0.79 | HTR6 (0.46) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL4387826 | 0.78 | OXER1 (0.50) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL18788892 | 0.78 | GABRG2 (0.43) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL7218364 | 0.78 | BUB1 (0.42) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL4150745 | 0.78 | USP30 (0.43) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL2003464 | 0.78 | NR1H2 (0.45) | PIK3CAPIK3CDABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| EP-3960180-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-03-02 | — | — | EP | disclosed |
| EP-3960180-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-03-02 | — | — | EP | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECH LTD (GB) | 2021-05-27 | — | — | US | disclosed |
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECH LTD (GB) | 2021-05-27 | — | — | US | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| CN-109195972-A | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 癌症研究科技有限公司 | 2019-01-11 | — | — | CN | disclosed |
| WO-2017178844-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | PIK3CA 145/4885PIK3CD 472/4885ABL1 23/4885 |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | PIK3CA 145/4885PIK3CD 472/4885ABL1 23/4885 |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, REL, BCR | PIK3CA 145/4885PIK3CD 472/4885ABL1 23/4885 |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, REL, BCR | PIK3CA 145/4885PIK3CD 472/4885ABL1 23/4885 |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | PIK3CA 145/4885PIK3CD 472/4885ABL1 23/4885 |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | RET, REL, BCR | PIK3CA 145/4885PIK3CD 472/4885ABL1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.